by lythamcorp | Oct 29, 2024 | Healthcare, Shuttle Pharmaceuticals
GAITHERSBURG, Md., Oct. 29, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation...
by lythamcorp | Oct 29, 2024 | Healthcare, NeurAxis News
CARMEL, Ind., Oct. 29, 2024 — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and...
by lythamcorp | Oct 29, 2024 | Healthcare, Precision Optics, Precision Optics News, Technology
GARDNER, Mass., Oct. 29, 2024 — Precision Optics Corporation, Inc. (NASDAQ: POCI) (“POC”), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced that its customer, a surgical...
by lythamcorp | Oct 29, 2024 | Healthcare, Shuttle Pharmaceuticals
GAITHERSBURG, Md., Oct. 29, 2024 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation...
by lythamcorp | Oct 29, 2024 | Healthcare, Kiora News, Kiora Pharmaceuticals
Encinitas, California–(October 29, 2024) – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) today announced it received regulatory approval to initiate a Phase 2 clinical trial to investigate KIO-301 for vision...